Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Cyclophosphamide/dactinomycin/vincristine

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Zhao D, et al. Efficacy and prognostic analysis of 125I brathytherapy combined with chemotherapy for pediatric parameningeal rhabdomyosarcoma. [Chinese]. Zhonghua Yi Xue Za Zhi 102: 1500-1505, No. 20, 31 May 2022. Available from: URL: https://rs.yiigle.com/cmaid/1379972 [Chinese; summarised from a translation] Zhao D, et al. Efficacy and prognostic analysis of 125I brathytherapy combined with chemotherapy for pediatric parameningeal rhabdomyosarcoma. [Chinese]. Zhonghua Yi Xue Za Zhi 102: 1500-1505, No. 20, 31 May 2022. Available from: URL: https://​rs.​yiigle.​com/​cmaid/​1379972 [Chinese; summarised from a translation]
Metadaten
Titel
Cyclophosphamide/dactinomycin/vincristine
Lack of efficacy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56788-z

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Ocrelizumab